Report date: July 30, 2026
Closing share price, July 29: $24.70
Central issue: Whether Baxter can validate the sharp second-half earnings recovery embedded in its full-year guidance.
Baxter already told investors that the second quarter would remain difficult: adjusted EPS should be similar to Q1’s $0.36, organic sales should improve sequentially but remain pressured year over year, and manufacturing-cost headwinds should be especially pronounced.
That makes the reported Q2 number less important than management’s confidence in the second half. Maintaining the midpoint of the 2026 EPS range would require adjusted EPS to rise from roughly $0.36 per quarter in the first half to about $0.62 per quarter in the second half. Investors therefore need evidence that the anticipated margin inflection is beginning—not another promise that improvement is one quarter away.
The stock also enters earnings with more optimism priced in. BAX has risen approximately 46% since April 29, the day before its Q1 report, and roughly 27% year to date. At $24.70, it trades at about 12.7 times the midpoint of management’s 2026 adjusted EPS guidance. The valuation remains undemanding, but the recent rally raises the bar for guidance quality and execution.
Management’s latest 2026 outlook called for:
| Metric | 2026 outlook |
|---|---|
| Reported sales growth | Flat to +1% |
| Organic sales growth | Approximately flat |
| FX contribution | Approximately +100 bps |
| Adjusted operating margin | 13%–14% |
| Adjusted EPS, continuing operations | $1.85–$2.05 |
| Net interest and other non-operating expense | $280M–$300M |
| Adjusted tax rate | 18.5%–19.5% |
| Diluted shares | Approximately 518M |
| Net tariff cost | Approximately $80M |
| Year-end net leverage target | Approximately 3x |
For Q2 specifically, management guided to:
A modest Q2 EPS beat would be welcome, but it would not resolve the central debate unless accompanied by better underlying margins or a more credible second-half outlook.
If Q2 adjusted EPS is approximately $0.36, first-half EPS would total about $0.72. Baxter would then need the following in the second half:
| Full-year outcome | Required 2H EPS | Average per quarter |
|---|---|---|
| Low end: $1.85 | $1.13 | $0.57 |
| Midpoint: $1.95 | $1.23 | $0.62 |
| High end: $2.05 | $1.33 | $0.67 |
Management previously described an approximately 500-basis-point operating-margin improvement from the first half to the second half, with three principal drivers:
The most important questions on the call should therefore be:
A reaffirmation without measurable evidence behind these items may not be enough after the stock’s recent run.
Beginning with Q2, Baxter will report two segments rather than three. The former Pharmaceuticals segment is now included within Infusion Therapies & Platforms, part of Medical Products & Therapies.
The recast segment consists of:
Recast Q1 results were:
The comparable Q2 2025 sales base is $1.95 billion.
This remains the largest source of execution risk. Q1 organic sales declined 3%, reflecting several separate pressures:
The IV-solutions comparison should become easier after Q2, and Baxter said pump revenue should grow in the second half as Spectrum offsets some Novum weakness. Investors should nevertheless focus on whether customers are remaining within Baxter’s broader pump-and-consumables ecosystem.
A useful result would include sequential improvement in Infusion Therapies & Platforms, no material Novum returns and evidence that injectables back orders are normalizing. Continued weakness in higher-margin injectable products would make the second-half margin ramp more difficult.
Advanced Surgery is Baxter’s clearest current growth asset. Organic sales grew 10% in Q1, supported by strong demand for hemostats and sealants and steady surgical volumes.
The Q2 2025 sales base is $296 million, after 5% operational growth last year. Investors should look for another high-single-digit or better performance. Material deceleration here would remove one of the few dependable offsets to weakness elsewhere in the portfolio.
HST includes:
Recast Q1 results were:
The comparable Q2 2025 sales base is $767 million.
Management expects HST’s growth to be weighted toward the second half, supported by its U.S. capital-equipment order book and product launches including Dynamo and Connex 360.
The key distinction is between orders and recognized revenue. Baxter has cited healthy hospital capital spending and a strong order book, but Care Communications installation timing and government-order timing in Front Line Care have delayed revenue. Investors should look for:
HST’s margin trajectory also deserves scrutiny. Another quarter near Q1’s depressed margin would increase the amount of improvement required in the final six months.
Baxter continues to assume that the Novum LVP shipment and installation hold remains in place for all of 2026. The company is finalizing hardware and software corrections and may need additional regulatory submissions.
Management has said:
The immediate P&L exposure is therefore relatively contained. The more important issues are customer retention, future consumables revenue and Baxter’s credibility in infusion systems.
Investors should listen for:
A concrete regulatory timeline would be positive, although current guidance does not require a 2026 relaunch.
Baxter made encouraging progress in Q1:
The improvement reflected better receivables collection and extended supplier payment terms. That is helpful, although some of the working-capital benefit may represent timing rather than a durable increase in earnings power.
Management continues to target approximately 3x net leverage by year-end, while the credit-rating outlooks from both S&P and Moody’s were moved to negative during Q1. With free cash flow expected to be back-half weighted, investors should examine:
A weak cash result would be concerning even if adjusted EPS meets expectations.
Baxter’s guidance includes approximately $80 million of net tariff costs, a roughly $40 million incremental year-over-year headwind. Management previously said current oil prices could be managed without a material additional 2026 impact.
Investors should look for any change in:
Baxter made progress clearing back orders at one internal manufacturing facility, but supply from a contract manufacturer is expected to remain limited into 2027. The mix impact is important because affected products include higher-margin injectables.
A recovery in total volume without a better product mix may provide less margin benefit than expected.
Anita Zielinski remained interim CFO at the time of Baxter’s July 14 segment-recasting filing. An update on the permanent CFO search would help reduce management-transition uncertainty as the company executes a complex operational and balance-sheet turnaround.
Baxter expects $130 million–$140 million of transition-services income and reimbursements in 2026. These earnings will eventually roll off. Investors should distinguish between improvement in the operating businesses and support from temporary Vantive arrangements.
This would be operationally acceptable, though the stock reaction could be muted given the recent rally.
A guide cut would challenge the core turnaround thesis because the existing outlook already incorporates a weak first half and depends heavily on second-half execution.
Baxter does not need to produce a strong Q2 in absolute terms; management explicitly prepared investors for another weak quarter. It does need to demonstrate that Q2 represents the trough.
The most constructive combination would be approximately $0.36 or better of adjusted EPS, stable underlying demand, no incremental Novum damage, positive free cash flow and concrete evidence that inventory absorption and cost reductions will lift second-half margins.
The key risk is that Baxter reiterates its annual targets while once again pushing the proof of recovery into the next quarter. With the shares up sharply since Q1, investors are likely to demand more than a nominal earnings beat—they need evidence that the projected second-half earnings step-up is already becoming visible.